Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

Multiple clinical trials have demonstrated that intravesical Bacillus Calmette–Guérin (BCG) treatment reduces recurrences and progression in patients with non-muscle-invasive bladder cancer (NMIBC). However, although BCG has been in use for almost 40 years, this agent is often underutilized and practice patterns of administration vary. This neglect is most likely caused by uncertainties about the optimal use of BCG, including unawareness of optimal treatment schedules and about patient populations that most benefit from BCG treatment. To address this deficit, a focus group of specialized urologic oncologists (urologists, medical oncologists and radiation oncologists) reviewed the current guidelines and clinical evidence, discussed their experiences and formed a consensus regarding the optimal use of BCG in the management of patients with NIMBC. The experts concluded that continuing therapy with 3-week BCG maintenance is superior to induction treatment only and is the single most important factor in improving outcomes in patients with NMIBC. They also concluded that a reliable alternative to radical cystectomy in truly BCG-refractory disease remains the subject of clinical trials. In addition, definitions for common terms of BCG failure, such as BCG-refractory and BCG-intolerant, have been formulated.

• Publication year

  2015

• Venue

  Nature reviews. Urology

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrurol.2015.58PMID 25800393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peripheral arterial disease: clinical and cost comparisons between duplex US and contrast- enhanced MR angiography-a multicenter randomized trial

  2017cited by this paper
• わが国における成人市中肺炎原因微生物についてのsystematic review/meta‐analysis

  2016cited by this paper
• National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

  2015cited by this paper
• Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin.

  2015cited by this paper
• Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer

  2015cited by this paper
• 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).

  2015cited by this paper
• Re: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2026; and Basic Health Program

  2014cited by this paper
• Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.

  2014cited by this paper
• Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

  2014cited by this paper
• cardiac magnetic resonance

  2014cited by this paper
• Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

  2014cited by this paper
• Functionalized gold nanorods for thermal ablation treatment of bladder cancer.

  2014cited by this paper
• The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette‐Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population

  2014cited by this paper
• The role of functional polymorphisms in immune response genes as biomarkers of BCG Immunotherapy outcome in bladder cancer : Establishment of a predictive profile in a Southern Europe population 1

  2014cited by this paper
• Inverse-square law

  2014cited by this paper
• Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base.

  2014cited by this paper
• Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.

  2014cited by this paper
• Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

  2014cited by this paper
• ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

  2013cited by this paper
• What is a randomised controlled trial?

  2013cited by this paper
• CORONARY ARTERY DISEASE Original Studies Outcomes of Concomitant Percutaneous Coronary Intervention and Balloon Aortic Valvuloplasty

  2013cited by this paper
• Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.

  2013cited by this paper
• The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.

  2013cited by this paper
• Bladder cancer.

  2013cited by this paper
• Bacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine

  2013cited by this paper
• SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.

  2013cited by this paper
• EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

  2013cited by this paper
• Bacillus Calmette‐Guérin immunotherapy for genitourinary cancer

  2013cited by this paper
• Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

  2013cited by this paper
• Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

  2013cited by this paper
• Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international individual patient data survey (IPDS)

  2013cited by this paper
• Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.

  2013cited by this paper
• The optimal management of T1 high-grade bladder cancer.

  2013cited by this paper
• Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer.

  2013cited by this paper
• Guidelines for pediatric cardiovascular centers.

  2013cited by this paper
• Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

  2013cited by this paper
• Intravesical chemotherapy plus bacille Calmette‐Guérin in non‐muscle invasive bladder cancer: a systematic review with meta‐analysis

  2013cited by this paper
• Effect of statin use on outcomes of non‐muscle‐invasive bladder cancer

  2013cited by this paper
• Aliskiren

  2012cited by this paper
• American College of Physicians Ethics Manual

  2012cited by this paper
• Indication and timing of cystectomy in high-risk bladder cancer

  2012cited by this paper
• Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement

  2012cited by this paper
• Association of Polymorphisms in Oxidative Stress Genes with Clinical Outcomes for Bladder Cancer Treated with Bacillus Calmette-Guérin

  2012cited by this paper
• Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.

  2012cited by this paper
• Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer

  2012cited by this paper
• Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.

  2012cited by this paper
• A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.

  2012cited by this paper
• FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation

  2012cited by this paper
• Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer

  2012cited by this paper
• Smac mimetic enables the anticancer action of BCG‐stimulated neutrophils through TNF‐α but not through TRAIL and FasL

  2012cited by this paper
• Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.

  2012cited by this paper
• Ethics in Cardiovascular Medicine

  2012cited by this paper
• Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

  2012cited by this paper
• A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin.

  2012cited by this paper
• Timing of events in STEMI patients treated with immediate PCI or standard medical therapy: implications on optimisation of timing of treatment from the CARESS-in-AMI trial.

  2012cited by this paper
• Valve in valve: another milestone for transcatheter valve therapy.

  2012cited by this paper
• Pathophysiology of Heart Failure

  2012cited by this paper
• Contrast-Induced Acute Kidney Injury

  2012cited by this paper
• Potential role of three-dimensional rotational angiography and C-arm CT for valvular repair and implantation

  2011cited by this paper
• Intracardiac echocardiography: a new guiding tool for transcatheter aortic valve replacement.

  2011cited by this paper
• Calcium Channel Blockers

  2011cited by this paper
• Transfemoral aortic valve implantation new criteria to predict vascular complications.

  2011cited by this paper
• Long‐term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin‐C alone as adjuvant treatment for non‐muscle‐invasive bladder cancer (NMIBC)

  2011cited by this paper
• CoreValve transcatheter aortic valve implantation via the subclavian artery: comparison with the transfemoral approach.

  2011cited by this paper
• Outcomes of Nonemergent Percutaneous Coronary Intervention With and Without On-site Surgical Backup: A Meta-Analysis

  2011cited by this paper
• Evaluation of aortic root for definition of prosthesis size by magnetic resonance imaging and cardiac computed tomography: implications for transcatheter aortic valve implantation

  2011cited by this paper
• Aortic valve replacement in octogenarians: outcome and predictors of complications.

  2011cited by this paper
• 2-year follow-up of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis.

  2011cited by this paper
• Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis.

  2011cited by this paper
• Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis.

  2011cited by this paper
• Health-Related Quality of Life After Transcatheter Aortic Valve Replacement in Inoperable Patients With Severe Aortic Stenosis

  2011cited by this paper
• Barriers to surgery in severe aortic stenosis patients with Class I indications for aortic valve replacement.

  2011cited by this paper
• First-in-man implantation of a trans-catheter aortic valve in a mitral annuloplasty ring: novel treatment modality for failed mitral valve repair.

  2011cited by this paper
• Coronary obstruction following transcatheter aortic valve‐in‐valve implantation for failed surgical bioprostheses

  2011cited by this paper
• Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

  2011cited by this paper
• Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set, 10th Edition

  2011cited by this paper
• Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic Stenosis

  2011cited by this paper
• Severe intraprosthetic regurgitation by immobile leaflet after trans-catheter aortic valve implantation.

  2011cited by this paper
• Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus

  2011cited by this paper
• Early and late (one year) outcomes following transcatheter aortic valve implantation in patients with severe aortic stenosis (from the United States REVIVAL trial).

  2011cited by this paper
• Outcomes of surgical aortic valve replacement in high-risk patients: a multiinstitutional study.

  2011cited by this paper
• Percutaneous coronary intervention at centers with and without on-site surgery: a meta-analysis.

  2011cited by this paper
• Impact of CONSORT extension for cluster randomised trials on quality of reporting and study methodology: review of random sample of 300 trials, 2000-8

  2011cited by this paper
• Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry.

  2011cited by this paper
• Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993)

  2011cited by this paper
• Health Risks from Exposure to Low Levels of Ionizing Radiation : BEIR VII Phase 2 4 / 10 / 2011

  2011cited by this paper
• Comprehensive assessment of frailty for elderly high-risk patients undergoing cardiac surgery.

  2011cited by this paper
• Off-hour primary percutaneous coronary angioplasty does not affect outcome of patients with ST-Segment elevation acute myocardial infarction treated within a regional network for reperfusion: The REAL (Registro Regionale Angioplastiche dell'Emilia-Romagna) registry.

  2011cited by this paper
• Transcutaneous aortic valve implantation using the axillary/subclavian access: feasibility and early clinical outcomes.

  2011cited by this paper
• Recognition and Treatment of BCG Failure in Bladder Cancer

  2011cited by this paper
• Direct renin inhibitors

  2011cited by this paper
• Transcatheter versus surgical aortic-valve replacement in high-risk patients.

  2011cited by this paper
• Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry.

  2011cited by this paper
• Multimodality imaging in transcatheter aortic valve implantation and post-procedural aortic regurgitation: comparison among cardiovascular magnetic resonance, cardiac computed tomography, and echocardiography.

  2011cited by this paper
• Heart failure

  2011cited by this paper
• Feasibility and accuracy of a comprehensive multidetector computed tomography acquisition for patients referred for balloon-expandable transcatheter aortic valve implantation.

  2011cited by this paper
• Permanent pacemaker implantation after transapical transcatheter aortic valve implantation.

  2011cited by this paper
• Effect of experience on results of transcatheter aortic valve implantation using a Medtronic CoreValve System.

  2011cited by this paper
• Maintenance therapy with bacillus Calmette‐Guérin Connaught strain clearly prolongs recurrence‐free survival following transurethral resection of bladder tumour for non‐muscle‐invasive bladder cancer

  2011cited by this paper
• Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches.

  2011cited by this paper

• Adjuvant bacillus Calmette-Guérin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naïve high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study.

  2026cites this paper
• Attenuated Bacteria-Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies.

  2026cites this paper
• Pathogen‐Mimicking Cancer Vaccine with Self‐Generated dsRNA Potentiates Innate Immunity Against Colon Cancer

  2025cites this paper
• Bacillus Calmette‐Guérin (BCG) and Interferon (IFN) Gene Therapy for Combination Bladder Cancer Treatment: A Mathematical Model for Improved Efficacy and Tolerability

  2025cites this paper
• Analysis of local and systemic side effects of bacillus Calmette-Guérin immunotherapy in bladder cancer: a retrospective study in Türkiye

  2025cites this paper
• Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer.

  2025cites this paper
• Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guérin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German health claims data

  2025cites this paper
• Combination regimen of intravesical docetaxel, gemcitabine, and cisplatin in patients with BCG-unresponsive bladder cancer: clinical outcomes and genomic correlations.

  2025cites this paper
• Identifying the internalization pathways of magnetotactic bacteria and magnetosomes by cancer cells

  2025cites this paper
• BCG Intolerance in Nonmuscle Invasive Bladder Cancer—A Systematic Review

  2025cites this paper
• Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers

  2025cites this paper
• Traditional and next-generation bacillus Calmette-Guérin based treatment strategies for bacillus Calmette-Guérin unresponsive non-muscle-invasive bladder cancer in the era of emerging therapies.

  2025cites this paper
• Bacterial carrier-mediated drug delivery systems: a promising strategy in cancer therapy

  2025cites this paper
• Urothelial Carcinoma In Situ: Advances in Diagnosis and Management.

  2025cites this paper
• Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers

  2025cites this paper
• Efficacy and safety of BCG and immune checkpoint inhibitors in non-muscle invasive bladder cancer: A meta-analysis with exploratory chemotherapy comparisons

  2025cites this paper
• A Comprehensive Review of Current Approaches in Bladder Cancer Treatment.

  2025cites this paper
• Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis

  2025cites this paper
• Review of BCG immunotherapy for bladder cancer

  2025cites this paper
• Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

  2025cites this paper
• The Rational Engineered Bacteria Based Biohybrid Living System for Tumor Therapy

  2024cites this paper
• Towards Understanding Tumour Colonisation by Probiotic Bacterium E. coli Nissle 1917

  2024cites this paper
• Comparative study on the efficacy of low-dose and full-dose BCG bladder perfusion therapy

  2024cites this paper
• Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

  2024cites this paper
• IP02-26 REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH BCG-EXPOSED PAPILLARY ONLY HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER

  2024cites this paper
• Bacterial membrane vesicles combined with nanoparticles for bacterial vaccines and cancer immunotherapy.

  2024cites this paper
• Emerging molecular therapies in the treatment of bladder cancer

  2024cites this paper
• Clinical Translation of Inorganic Nanoparticles and Engineered Living Materials for Cancer Therapy.

  2024cites this paper
• Mycobacteria Treatment Inhibits Bladder Cancer Cell Migration, Invasion, and Anchorage-Independent Growth

  2024cites this paper
• Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer.

  2024cites this paper
• BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies

  2024cites this paper
• Effect of Bacillus Calmette-Guérin Instillation Timing on Oncological Survivals after Transurethral Resection of Bladder Tumor.

  2024cites this paper
• STING Agonist VB-85247 Induces Durable Antitumor Immune Responses by Intravesical Administration in a Non–Muscle-Invasive Bladder Cancer

  2024cites this paper
• Perfusion drugs for non‑muscle invasive bladder cancer (Review)

  2024cites this paper
• Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro

  2024cites this paper
• A comprehensive analysis of FBN2 in bladder cancer: A risk factor and the tumour microenvironment influencer

  2023cites this paper
• A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer

  2023cites this paper
• Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients

  2023cites this paper
• Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK

  2023cites this paper
• Chemo-immunoablation of solid tumors: A new concept in tumor ablation

  2023cites this paper
• Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients?

  2023cites this paper
• Continued Use and Expansion of Photodynamic TURBT

  2023cites this paper
• Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023

  2023cites this paper
• Combining in situ vaccination and immunogenic apoptosis to treat cancer.

  2023cites this paper
• Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs

  2023cites this paper
• Trial watch: Toll-like receptor ligands in cancer therapy

  2023cites this paper
• The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma

  2023influential citation
• Real‐world treatment patterns and clinical outcomes of Japanese patients with non‐muscle invasive bladder cancer receiving intravesical bacillus Calmette–Guérin treatment

  2022cites this paper
• Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer

  2022cites this paper
• Proteomic networks associated with tumor-educated macrophage polarization and cytotoxicity potentiated by heat-killed tuberculosis

  2022cites this paper
• Bacteria in cancer therapy: A new generation of weapons

  2022cites this paper
• Antibiotics and BCG

  2022cites this paper
• Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment

  2022cites this paper
• Editorial Comment from Dr Matsumoto to Real‐world treatment patterns and clinical outcomes of Japanese patients with non‐muscle invasive bladder cancer receiving intravesical bacillus Calmette–Guérin treatment

  2022cites this paper
• The past, present, and future of immunotherapy for bladder tumors

  2022cites this paper
• The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis

  2022cites this paper
• Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors

  2022cites this paper
• An Individualized Prognostic Signature for Clinically Predicting the Survival of Patients With Bladder Cancer

  2022cites this paper
• Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): Systematic review and network meta-analysis according to EAU COVID-19 recommendations

  2022cites this paper
• Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.

  2022cites this paper
• Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guérin: Implications for Risk-adapted Follow-up.

  2022cites this paper
• Editorial Comment from Dr Taoka and Dr Sugimoto to Real‐world treatment patterns and clinical outcomes of Japanese patients with non‐muscle invasive bladder cancer receiving intravesical bacillus Calmette–Guérin treatment

  2022cites this paper
• BCG in Bladder Cancer Immunotherapy

  2022cites this paper
• Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model.

  2021cites this paper
• Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma

  2021cites this paper
• Customized materials-assisted microorganisms in tumor therapeutics.

  2021cites this paper
• Trial watch: intratumoral immunotherapy

  2021cites this paper
• Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)

  2021cites this paper
• Immune escape mechanisms and immunotherapy of urothelial bladder cancer

  2021cites this paper
• Robotic cystectomy histopathology outcomes in patients who have ‘failed’ Bacillus Calmette–Guérin: A case series

  2021cites this paper
• Emerging Applications of Bacteria as Antitumor Agents.

  2021cites this paper
• The Microbiome and Urologic Cancers

  2021cites this paper
• Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study

  2021cites this paper
• Post-Bacille Calmette–Guerin surveillance for non-muscle invasive bladder cancer: do random biopsies offer an advantage?

  2021cites this paper
• The double-sided effects of Mycobacterium Bovis bacillus Calmette–Guérin vaccine

  2021cites this paper
• The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis

  2021cites this paper
• Role of Immunomodulation of BCG Therapy on AML Remission

  2021cites this paper
• Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer

  2021cites this paper
• Educational Case: Bladder Urothelial Cell Carcinoma TNM Stage, Prognosis and Management

  2021cites this paper
• The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non–muscle‑invasive Bladder Cancer

  2021cites this paper
• The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review.

  2020cites this paper
• Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study

  2020cites this paper
• Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives

  2020cites this paper
• Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer

  2020cites this paper
• Carcinoma in situ of the bladder: why is it underdetected?

  2020cites this paper
• Competitive glucose metabolism as a target to boost bladder cancer immunotherapy

  2020cites this paper
• PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders

  2020cites this paper
• Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer

  2020cites this paper
• Management of bladder cancer in older patients: Position paper of a SIOG Task Force.

  2020cites this paper
• Bladder Cancer in Older Adults

  2020cites this paper
• Glycemic impact of a diet and lifestyle intervention on diabetics and prediabetics during treatment for non-muscle invasive bladder cancer

  2020cites this paper
• Engineering commensal bacteria to rewire host-microbiome interactions.

  2020cites this paper
• Carcinoma In Situ of the Urinary Bladder: A Systematic Review of Current Knowledge Regarding Detection, Treatment, and Outcomes.

  2020cites this paper
• Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit

  2020cites this paper
• Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy

  2020cites this paper
• Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.

  2020cites this paper
• Magnetotactic bacteria for cancer therapy

  2020cites this paper
• Overcoming immune dysfunction in the elderly: trained immunity as a novel approach

  2020cites this paper
• Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes

  2020cites this paper
• Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications

  2020cites this paper